Pharmafile Logo
Pharmafocus logo
Advanced Search

Nouscom Presents New Positive Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy, in a Late-Breaking Abstract at AACR 2023

April 18, 2023
Business Services

BASEL, Switzerland – 18th April 2023 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector immunotherapies, …

News
Press release

MED3000, Eroxon® UK Launch

April 18, 2023
Business Services

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on …

News
Press release

Scancell to present ModiFY Phase 1/2 cancer vaccine clinical trial protocol and early efficacy data at the American Association for Cancer Research Annual Meeting

April 18, 2023
Business Services

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces it …

News
Press release

GSK enters into £1.6bn deal to acquire Bellus Health

April 18, 2023
Medical Communications

UK-based GSK has announced its plans to acquire Bellus Health, a Canadian late-stage biopharmaceutical company which focuses on treatments for …

News

Ariceum Therapeutics announces extension of Series A financing for radiopharmaceutical clinical pipeline

April 18, 2023
Sales and Marketing

Private biotech company Ariceum Therapeutics has announced the successful completion of Series A extension financing, raising an additional €22.75m following …

News
yunus-tug-lnfgdbcajxu-unsplash

Gamida Cell’s Omisirge receives FDA approval

April 18, 2023
Research and Development

Cell therapy pioneer Gamida Cell has announced FDA approval of its allogeneic cell therapy, Omisirge (omidubicel-onlv), for use in adult …

News
nik-shuliahin-bunwp1bl0nc-unsplash

FDA approves expanded indication for AbbVie’s chronic migraine treatment

April 18, 2023
Medical Communications

US-based AbbVie has announced that the FDA has granted approval for the expanded indication of its preventative chronic migraine treatment …

News

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer

April 18, 2023
Business Services

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, April 18, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces …

News
Press release

We need more “trial” and less error – a concerted effort is required to include more people aged over 60 in clinical trials, argues longevity experts

April 18, 2023
Business Services

The Trial and error report, published today, urges regulators, pharmaceutical companies and researchers to prioritise age diversity at all stages …

News
Press release

Cantargia presents new clinical data at AACR 2023 strongly supporting nadunolimab development in pancreatic cancer

April 17, 2023
Business Services

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today presented updated interim clinical efficacy data including subgroup analyses of first-line pancreatic cancer …

News
Press release

ClinOne Closes Series A Funding Round to Scale its Site and Participant Engagement Platform, Data Driven Insights and Interoperability

April 17, 2023
Business Services

BOSTON AND BOULDER, COLO. (PRWEB) APRIL 13, 2023 – ClinOne, the leading provider of Adaptive Experiences in clinical trials announced …

News
Press release

Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favourable Tolerability and Immunogenicity Profile

April 17, 2023
Business Services

OXFORD, United Kingdom, April 17, 2023 (GLOBE NEWSWIRE) – Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company focused on the …

News
Press release

ECCMID 2023: Shionogi Announces Real-World Evidence Demonstrating the Efficacy of Fetcroja (cefiderocol) Against Some of the Most Difficult-to-Treat Gram-Negative Bacterial Pathogens

April 17, 2023
Business Services

OSAKA, Japan, APRIL 17, 2023 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; …

News
Press release

PureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID

April 17, 2023
Business Services

CAMBRIDGE, MA, April 17, 2023 – Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based …

News
Press release
national-cancer-institute-kluafqlacfw-unsplash

Companies showcase innovative biotech at American Association for Cancer Research

April 17, 2023
Medical Communications

Leading companies in the biotechnology sector will showcase their latest innovations at the American Association for Cancer Research (AACR) meeting …

News

Complement Therapeutics gains €72m in Series A financing for novel therapeutics research

April 17, 2023
Medical Communications

Preclinical stage biotechnology company Complement Therapeutics (CTx) has announced the completion of its Series A financing round, led by Gimv, …

News
towfiqu-barbhuiya-ssz6x-gao0c-unsplash

GSK announces positive data from phase 3 trial for new UTI antibiotic

April 17, 2023
Research and Development

GSK has shared positive data from its phase 3 trial for gepotidacin as a new oral antibiotic for the treatment …

News
volodymyr-hryshchenko-m1hq4ibp9rc-unsplash

Merck acquires Prometheus Biosciences, strengthens immunology pipeline

April 17, 2023
Sales and Marketing

Merck (known as MSD outside of the US and Canada) has announced that it, through a subsidiary, has agreed to …

News

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

April 17, 2023
Business Services

BOSTON and WILMINGTON, Del. – April 16, 2023 – MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: …

News
Press release

MinervaX Commences First Phase 1 Clinical Study of Novel GBS Vaccine in Older Adults

April 17, 2023
Business Services

Copenhagen, Denmark, 17 April 2023 – MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group …

News
Press release
The Gateway to Local Adoption Series

Latest content

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026